Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

OBJECTIVE: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). METHODS: Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Pranay, Mostaghim, Anahita, Bielick, Catherine G., McLaughlin, Angela, Hamer, Davidson H., Wetzler, Lee M., Bhadelia, Nahid, Fagan, Maura A., Linas, Benjamin P., Assoumou, Sabrina A., Ieong, Michael H., Lin, Nina H., Cooper, Ellen R., Brade, Karrine D., White, Laura F., Barlam, Tamar F., Sagar, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591937/
https://www.ncbi.nlm.nih.gov/pubmed/32721528
http://dx.doi.org/10.1016/j.ijid.2020.07.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591937/
https://www.ncbi.nlm.nih.gov/pubmed/32721528
http://dx.doi.org/10.1016/j.ijid.2020.07.023

Ejemplares similares